November 20, 2025

Exclusive: Beacon Biosignals raises $86M to build and mine brain data trove

IntelME Verdict

R&D Advance

TL;DR

Beacon Biosignals secures $86M in Series B funding to enhance precision medicine data platform, develop neurodiagnostic dataset, and accelerate biomarker discovery for CNS drug development.

Analysis

Beacon Biosignals' $86M funding for neurodiagnostic dataset and biomarker discovery using AI-driven EEG analytics signifies a significant R&D advance in CNS drug development. This development could lead to improved patient selection for neurological and psychiatric diseases, potentially revolutionizing treatment approaches in these therapeutic areas.

Source

Endpoints News↗